Ascletis Pharma Inc. ASCLF
0.72 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.72 Day range 0.72
0.72 52-week range 2.50
- YTD
- -51.68%
- 1 year
- -40.00%
- Market cap
- 753.92M
- EPS (ttm)
- -0.08
- YTD return
- -51.68%
- 1-year return
- -40.00%
- Volume
- 5.00K
- Avg volume
- 928
- Open
- 0.72
- Previous close
- 0.72
- Day's range
- 0.72 – 0.72
- 52-week range
- 0.72 – 2.50
- Earnings date
- Aug 31, 2026
2Y +0.5633 (+359.48%)
Next earnings
Aug 31, 2026
Expected Aug 31, 2026. Consensus EPS estimate -0.02944.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 31, 2026 | Jun 30, 2026 | -0.02944 | — | — | — |
| Mar 31, 2026 | Dec 31, 2025 | -0.04003 | -0.04003 | 0.00 | 0.00% |
| Aug 15, 2025 | Jun 30, 2025 | -0.01814 | -0.01275 | +0.01 | +29.71% |
| Mar 26, 2025 | Mar 31, 2025 | -0.02054 | -0.02328 | 0.00 | -13.34% |
| Aug 30, 2024 | Jun 30, 2024 | -0.01651 | -0.01764 | 0.00 | -6.84% |
| May 22, 2024 | Mar 31, 2024 | 0.00147 | — | — | — |
News
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity 
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) 
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions 
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes 
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development 
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity 
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development 
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes 
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Your note
Sign in to keep a note on ASCLF — it syncs with the Stock Master app.